We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
United Biomedical’s nonprofit vaccine subsidiary, Covaxx, said it has secured supply deals worth $2.8 billion for more than 140 million doses of its COVID-19 vaccine candidate, UB-612, in “multiple countries,” including Brazil, Ecuador and Peru. Read More
Merck is expanding further into the biotech sector by acquiring Rockville, Md., biopharma company OncoImmune for $425 million, netting in the process an investigational drug that has shown promise as a treatment for hospitalized COVID-19 patients. Read More
As some of the world’s largest drugmakers gear up to manufacture and distribute COVID-19 vaccines, a relatively tiny competitor, Massachusetts-based Moderna, faces some unique challenges. Read More
Previously, Lilly said it expects to manufacture up to 1 million doses of the 700-mg dose of bamlanivimab globally by the end of the year and anticipates supply to increase significantly in the first quarter of 2021. Read More
Three large European investors are teaming up to form a $750 million company to create biopharmaceuticals businesses in Africa aiming to broaden the range of therapeutics available in the underserved markets there. Read More
Eli Lilly and South Korea’s Samsung Biologics have forged a long-term partnership to expand the Indianapolis, Ind.-based drugmaker’s supply of COVID-19 neutralizing antibody treatments, amid concerns about shortages as coronavirus cases spike globally. Read More
Amazon has launched an online prescription drug service, Amazon Pharmacy, that enables customers to order home delivery of prescriptions using their mobile devices. Read More
German drugmaker CureVac is scaling up its manufacturing capability in the European Union and plans to ship 300 million doses of its COVID-19 vaccine, CVnCoV, across the world next year and 600 million doses in 2022. Read More